Adam S. Mostafa

Chief Financial Officer and Head of Business Development at Sitryx Therapeutics

Speaker

Adam is currently the Chief Financial Officer and Head of Business Development for Sitryx Therapeutics. He joined Sitryx from X4 Pharmaceuticals (NASDAQ: XFOR), a hematology and immunology focused rare disease company, where he also served as Chief Financial Officer and Head of Business Development and helped lead the company from clinical development to FDA approval and launch of XOLREMDI(r). Prior to joining X4, Mr. Mostafa served as Chief Financial Officer and Head of Business Development of Abpro Corporation, a biotechnology company focused on antibody therapeutics, where he led the formation of multiple collaborations, capital raises and IPO preparations. Prior to that, Mr. Mostafa held a number of senior investment banking and portfolio management positions, including Managing Director in the healthcare investment banking group at Cantor Fitzgerald, Senior Vice President in the healthcare investment banking group at Needham & Company, Vice President at CRT Capital Group, and portfolio management responsibilities in the global stock selection group at AQR Capital. Adam began his career as an analyst in the healthcare investment banking group at Salomon Smith Barney. Adam is also on the Board of Directors, and Chairs the Audit Committee, of Satellos Biosciences (NASDAQ: MSLE) and Precision Biologics. Adam also leads Corporate Development activities for Cumberland Pharmaceuticals (NASDAQ: CPIX). Mr. Mostafa holds a A.B. in Economics from Brown University.